ZURICH/BERLIN, Nov 11 (Reuters) - The Swiss blue-chip SMI was seen opening -0.2% at 10,286 points on Monday, according to premarket indications by bank Julius Baer .
Here are some of the main factors that may affect Swiss stocks on Monday:
Novartis us buying the Japanese generics operations of South Africa’s Aspen Pharmacare in a deal worth up to 400 million euros ($440.80 million) to expand in the world’s third-biggest drug market, the Swiss drugmaker said on Monday.
Roche’s Swiss drug development organisation is due to highlight cancer, neurology and ophthalmology drugs in its pipeline.
Separately it said its drug risdiplam helped people with type 2 or 3 spinal muscular atrophy improve their motor function, as the Swiss drugmaker presses ahead with a medicine it sees rivalling Biogen’s BIIB.O Spinraza and Novartis’s NOVN.S Zolgensma.
Executive board member Iqbal Khan wants to expand credit to rich clients as a way to grow the bank’s wealth management business, SonntagsZeitung reported.
Credit Suisse CSGN.S is making changes to its executive board, the bank said on Monday, appointing David Miller as Chief Executive of its investment banking and capital markets business.
Givaudan is buying U.S. flavour and fragrance maker Ungerer & Company, the Swiss company said as it presses ahead with its growth strategy.
The speciality chemicals maker is examining a list of 20 candidates for its chief executive role, chairman and interim CEO Hariolf Kottmann told NZZ am Sonntag in an interview.
Schmolz & Bickenbach will ask its shareholders for permission to raise up to 614.25 million Swiss francs ($616.16 million) in new capital at its upcoming extraordinary general meeting, the embattled Swiss steelmaker said on Monday.
* Implenia Chairman Hans Ulrich Meister said an IPO for the company’s real estate business would be in the realm of possibility, but ideally after it has reached a volume of 2-3 billion francs, according to an interview in Finanz & Wirtschaft.
* Cembra Money Bank said its cashgate subsidiary of Cembra has reached an agreement with a group of real estate management companies to sell the rental guarantee business currently operating under the SmartCaution brand.
* Clariant wants a combined $2.5 billion for masterbatches and pigments assets it has been seeking to sell, Tages-Anzeiger reported, citing company circles.
* Glarner Kantonalbank announces collaboration with Klara to link business software to e-banking.
* No major Swiss economic data scheduled (Reporting by Zurich newsroom and Berlin Speed Desk)